We’re excited to announce the launch of Moonwalk Biosciences, a genomic medicine company pioneering precision epigenetic medicines, with $57 million in financing from Alpha Wave Global, ARCH Venture Partners, Future Ventures, GV (Google Ventures), Khosla Ventures and YK Bioventures. By targeting the epigenetic code – the software of the genome – Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed. Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases. Learn more here: https://moonwalk.bio/ Read our press release: https://lnkd.in/gcuF7Umy More info about us in: WSJ: https://lnkd.in/e5_6R2y2 STAT: https://lnkd.in/eViTRJqE Endpoints News: https://lnkd.in/eSySAyWd Biopharma Dive: https://lnkd.in/ei8wKM2n
Moonwalk Biosciences
Biotechnology Research
South San Francisco, California 1,558 followers
Pioneering precision epigenetic medicines.
About us
Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.
- Website
-
https://moonwalk.bio
External link for Moonwalk Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
2 Tower Pl
South San Francisco, California 94080, US
Employees at Moonwalk Biosciences
Updates
-
Excited to kick off Day 1 at #JPM24 for Moonwalk! Thanks Nasdaq team for the celebratory message about our recent $57M funding! 🎉🎉🎉 Read the release: 👇👇👇 https://lnkd.in/gcuF7Umy
-
Genetic Engineering & Biotechnology News speaks with CEO Alex Aravanis MD PhD for the Touching Base podcast. 🧬🧬 Thanks Uduak Grace Thomas for taking the time to speak with us about #epigenetic #engineering and Moonwalk. Listen here: 👇👇 https://lnkd.in/eXJN5k2M
Novartis and Voyager, JPM Ahead, Epigenetic Engineering; Alex Aravanis | Touching Base
shows.acast.com
-
Join our CEO Alex Aravanis MD PhD next week at #JPM24. He will be on a panel on #AI and #MachineLearning next Tuesday Jan 9th at 9 am PT at #BiotechShowcase. AI & Machine Learning: Disrupting and Inspiring Location: Imperial Ballroom, Hilton Union Square SF The disruption and innovation of AI is coming and along with it the big tech players who have driven AI in other industries and areas. This panel of experts will discuss how AI is impacting the world of healthcare today and what we can expect in 2024 and beyond. Moderator: Beth Rogozinski, CEO, Oncoustics Panelists: Abraham Heifets, CEO, Atomwise Alex Aravanis MD PhD, CEO, Moonwalk Biosciences Andrei Georgescu, Ph.D., CEO, Vivodyne Kurt Thorn, VP, ArrePath More information about the event: https://lnkd.in/eZaESEs
-
Thanks NYSE for celebrating our $57M funding and coming out of stealth launch with us! 🎉🎉🎉 We’d like to thank all our supporters, our team of #Moonwalkers, our investors and advisors. 🌖🌗🌘 Read our release: https://lnkd.in/gcuF7Umy
-
Thanks FirstWord Pharma and Elizabeth Eaton for speaking with our CEO Alex Aravanis MD PhD today about our launch and coming out of stealth! Mapping methylation While traditional gene editing usually involves cutting, nicking, or removing DNA sections, epigenetics regulate whether a gene is “on” or “off” without physically changing the DNA itself. Moonwalk aims to modify gene expressions associated with disease by modulating the methylation patterns that determine cell states. In an interview with FirstWord, Aravanis, Moonwalk’s CEO, said methylation acts as a kind of switch that determines which genes are allowed to be expressed, and which ones aren’t. “This is the single most important thing which controls which of many genes in the genome hardware are going to be used in any particular cell,” he said. Read the full article: https://lnkd.in/eWVUmXE8
-
Moonwalk Biosciences reposted this
Thrilled to welcome Alex Aravanis MD PhD and the Moonwalk Biosciences team to the KV portfolio! 🎉 Moonwalk is using epigenetics - "the software of the genome" - to treat various diseases. https://lnkd.in/gXCukZEJ
-
Thanks Ron Leuty San Francisco Business Times for speaking with our CEO Alex Aravanis MD PhD about our $57M funding announcement today. Read the article: (subscription required) https://lnkd.in/epRs_QvE
Peninsula startup Moonwalk looks to rewire 'monster control switch' to change course of diseases - San Francisco Business Times
bizjournals.com
-
Moonwalk Biosciences reposted this
Welcome to the portfolio, Moonwalk Biosciences, Alex Aravanis MD PhD, Arash Jamshidi, and Justin Valley! 🎉 Moonwalk aims to reprogram cells to their healthy state with epigenetic editing, a new approach that enables scientists to restore diseased cells — https://on.wsj.com/3RJRDsd
Moonwalk Bio Grabs $57 Million, Joins Push for ‘Epigenetic’ Treatments
wsj.com
-
Genetic Engineering & Biotechnology News speaks with our CEO Alex Aravanis MD PhD about #epigenetic #engineering. Listen to their podcast tomorrow which will feature segments of the interview! Read the article: 👇👇👇 https://lnkd.in/euBqn8dP
Moonwalk Biosciences Raises $57M to Edit the Epigenome
genengnews.com